Roche Holding AG (RHHBY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to Roche's first quarter sales webinar 2025. My name is Henrik and I'm the technical operator for today's call. Kindly note that the webinar is being recorded. I'd like to inform you that all participants are in listen-only mode during the call. After the presentation, there will be a question and answer session. You're invited to send in questions for this throughout the entire session using the Q&A functionality of Zoom. In addition to that, you may also raise your virtual hand to address your questions verbally. for participants joining via phone, to raise your hand to star nine on your phone's star pad. When you then get selected to ask your questions, please follow the instructions from the phone and press star six to unmute yourself. One last remark, if you'd like to follow the presented slides on your end as well, please feel free to go to www.woosh.com slash investors to download the presentation. At this time, it's my pleasure to introduce you to Thomas Schieneker, CEO of Woosh Group. Mr. Schieneker, the stage is yours. Thank you very much. And I'm happy to share our Q1 2025 sales with you today. Now, let's look at our performance. We had really a good start in 2025 with group sales growing 6%. And this was driven by pharma with, again, very strong sales growth of 8%. So you can see that we continue our very strong momentum on the pharma side. Diagnostics was flat, and this was due to healthcare pricing reforms in China. Matt will cover that. Again, this did not only impact us, it impacted the entire industry. And this is something that we had flagged also at the full year results presentation in January. The LOE impact was also in line with guidance. So now let's look at the key milestones in Q1. On the pharma regulatory side, ...